ORG Wealth Partners
STLN icon

ORG Wealth Partners’s Starling Oncology STLN Stock Holding History

ORG Wealth Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$353 Buy
+56
New +$335 ﹤0.01% 2195

Other funds holding STLN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

ORG Wealth Partners's STLN Position: Q3 2026 in Review

ORG Wealth Partners opened a new position in Starling Oncology (STLN) in Q3 2026: 56 shares worth $353. The stake represents ﹤0.01% of the portfolio and ranks #2195 among its holdings.

71 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • ORG Wealth Partners held 56 shares of Starling Oncology worth $353 as of Q3 2026.
  • Starling Oncology was a new ORG Wealth Partners position in Q3 2026.
  • Starling Oncology made up ﹤0.01% of ORG Wealth Partners's portfolio in Q3 2026, its #2195 holding.
  • 71 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on ORG Wealth Partners's 13F filing for Q3 2026, filed 3 Nov 2026.